<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02989012</url>
  </required_header>
  <id_info>
    <org_study_id>DalianZhen-Ao</org_study_id>
    <nct_id>NCT02989012</nct_id>
  </id_info>
  <brief_title>Phase IIaTrials of GanMaoKangNing Granules</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dalian Zhen-Ao Bio-Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dalian Zhen-Ao Bio-Tech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, double- simulation, positive drug-and-Placebo-Controlled,
      multicenter, phase IIa clinical trials Study about GanMaoKangNing Granules in improving the
      symptoms of influenza.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flu recovery time</measure>
    <time_frame>six days</time_frame>
    <description>All the time needed for symptoms eased that from medication to fever and headache, muscle joint pain, chills, fatigue, cough, sore throat and a stuffy nose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single symptom remission rate</measure>
    <time_frame>six days</time_frame>
    <description>After the medication and three days later, The proportion of each individual symptoms of subjects which include of headache, muscle joint pain, chills, fatigue, cough, sore throat and a stuffy nose.
Symptoms defined as symptom scores dropped to 0 or 1 minute, and maintain for 24 h or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The antifebrile effect</measure>
    <time_frame>six days</time_frame>
    <description>Antifebrile rate: After the medication and three days later, the percentage of Body temperature returned to normal subjects (the axillary temperature &lt; 37.1 ℃, and maintain of 24 h or more time).
Medicine antifebrile time (h) : Medication for the first time to the axillary temperature &lt; 37.1 ℃, and maintain of 24 h or more time.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The conditions of drug utilization of the antipyretic and some cough medicine</measure>
    <time_frame>six days</time_frame>
    <description>Including acetaminophen tablets and capsule of dextromethorphan hydrobromide usage rate and dose.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Epidemic Influenza</condition>
  <arm_group>
    <arm_group_label>Drugs for experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GanMaoKangNing Granules， blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous Oseltamivir Phosphate Capsules,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drugs for control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Oseltamivir Phosphate Capsules ,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous GanMaoKangNing Granules, blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GanMaoKangNing Granules</intervention_name>
    <description>3 times a day, 2 bags each time.</description>
    <arm_group_label>Drugs for experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Analogous Oseltamivir Phosphate Capsules</intervention_name>
    <description>2 times a day,1 capsule each time.</description>
    <arm_group_label>Drugs for experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir Phosphate Capsules</intervention_name>
    <description>2 times a day,1 capsule each time.</description>
    <arm_group_label>Drugs for control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Analogous GanMaoKangNing Granules</intervention_name>
    <description>3 times a day, 2 bags each time.</description>
    <arm_group_label>Drugs for control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign the informed consent;

          -  Male and female patients aged between 18 and 65 years old , there is no limit on the
             gender;

          -  In line with the diagnostic criteria for pandemic influenza;

          -  Duration less than 48 (Duration is defined as the time from onset to test drugs for
             the first time before, the onset time pointed out that now the axillary temperature
             38.0 ℃, headache, muscle or joint pain, chills, fatigue, cough, sore throat and a
             stuffy nose eight any flu symptoms and signs in time);

          -  The axillary temperature is 38.0 ℃ or higher;

          -  Nose and throat swabs rapid virus antigen test result is positive.

        Exclusion Criteria:

          -  Severe influenza and of patients with complications of influenza.

          -  With the following any severe risk factors:

        A. With chronic respiratory diseases such as bronchial asthma, chronic obstructive
        pulmonary disease (copd), etc.

        B. with chronic diseases of the cardiovascular system, such as congestive heart failure,
        high blood pressure.

        C. with chronic metabolic and endocrine system diseases, such as poorly controlled diabetes
        (HbA1c 7.0% or higher).

        D. with chronic kidney disease, chronic liver disease, blood system diseases, neurological
        and neuromuscular diseases (such as epilepsy, cognitive impairment, etc.).

        E. A weakened immune system, such as long-term use of immunosuppressive agents, HIV
        infection or tumor.

        F. Under the age of 19, long-term aspirin use. G. The obese (BMI BMI &gt; 30).

          -  With influenza complications, such as secondary bacterial pneumonia and other
             pathogenic bacteria and other viral pneumonia caused by pneumonia.

          -  A history of peptic ulcer disease or gastrointestinal bleeding.

          -  Into the group received within 48 h before flu antiviral treatment.

          -  Into the group of 12 months before been vaccinated against the flu.

          -  Into the group used within 2 weeks before the monoamine oxidase inhibitors.

          -  Blood leukocyte count &gt; 10.0 x 109 / L, neutrophils ratio &gt; 80%, or the need for
             systemic antibiotic therapy.

          -  For GanMaoKangNing Granules, Oseltamivir Phosphate Capsules, Acetaminophen Tablets,
             Dextromethorphan Hydrobromide Capsule, GanMaoKangNing Granules simulation agent or
             Oseltamivir Phosphate Capsules simulation agent composition of allergy, or allergic
             constitution.

          -  Aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) ≥ 1.5 x Upper Limit
             Normal (ULN)， Scr &gt; Upper Limit Normal (ULN).

          -  Doubt or does have a history of alcohol or drug abuse.

          -  Pregnancy (defined as the pregnancy test positive), nursing mothers, or past in family
             planning.

          -  For nearly three months participated in other clinical trials of patients.

          -  Researchers think not appropriate to participate in this clinical subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University</name>
      <address>
        <city>Beijing Shi</city>
        <state>Beijing</state>
        <zip>100010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Wang Jing Wang, Dr.</last_name>
      <phone>010-64011516</phone>
      <email>lunlihui@163.com</email>
    </contact>
    <investigator>
      <last_name>QingQuan Liu Liu QingQuan, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.who.int/mediacentre/factsheets/fs211/en/.</url>
    <description>WHO. Influenza（Seasonal）[EB/OL].[2015-12-31]</description>
  </link>
  <link>
    <url>http://www.sda.gov.cn/WS01/CL0087/165165.html</url>
  </link>
  <link>
    <url>http://www.sda.gov.cn/WS01/CL1616/90958.html</url>
    <description>CFDE，Prevention and/or treatment of flu drug clinical research guiding principles，Released in 2012.</description>
  </link>
  <link>
    <url>http://www.jamanetwork.com/journals/jama/fullarticle/192425</url>
    <description>CFDE，Prevention and/or treatment of flu drug clinical research guiding principles，Released in 2012.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2016</study_first_submitted>
  <study_first_submitted_qc>December 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2016</study_first_posted>
  <last_update_submitted>December 7, 2016</last_update_submitted>
  <last_update_submitted_qc>December 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

